Flutamide-hydroxypropy-beta-chiyclodextrin complex: formulation, physical characterization, and absorption studies using the Caco-2 in vitro model.
about
Cyclodextrins in drug delivery: an updated reviewDose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-Dehydropregnenolone.Novel ionically crosslinked casein nanoparticles for flutamide delivery: formulation, characterization, and in vivo pharmacokinetics.Formulation and optimization of orodispersible tablets of flutamidePreparation, characterization, and in vitro intestinal permeability evaluation of thalidomide-hydroxypropyl-β-cyclodextrin complexes.Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes.
P2860
Flutamide-hydroxypropy-beta-chiyclodextrin complex: formulation, physical characterization, and absorption studies using the Caco-2 in vitro model.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Flutamide-hydroxypropy-beta-ch ...... ing the Caco-2 in vitro model.
@ast
Flutamide-hydroxypropy-beta-ch ...... ing the Caco-2 in vitro model.
@en
type
label
Flutamide-hydroxypropy-beta-ch ...... ing the Caco-2 in vitro model.
@ast
Flutamide-hydroxypropy-beta-ch ...... ing the Caco-2 in vitro model.
@en
prefLabel
Flutamide-hydroxypropy-beta-ch ...... ing the Caco-2 in vitro model.
@ast
Flutamide-hydroxypropy-beta-ch ...... ing the Caco-2 in vitro model.
@en
P2093
P1476
Flutamide-hydroxypropy-beta-ch ...... sing the Caco-2 in vitro model
@en
P2093
P304
P407
P577
2000-05-01T00:00:00Z